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Abstract
Objective: Roux-en-Y gastric bypass (RYGB) surgery is currently the most effective treatment for diabetes and obesity. 
An increasingly recognized and highly disabling complication of RYGB is postprandial hypoglycaemia (PPH). The 
pathophysiology of PPH remains unclear with multiple mechanisms suggested including nesidioblastosis, altered 
insulin clearance and increased glucagon-like peptide-1 (GLP-1) secretion. Whilst many PPH patients respond to 
dietary modification, some have severely disabling symptoms. Multiple treatments are proposed, including dietary 
modification, GLP-1 antagonism, GLP-1 analogues and even surgical reversal, with none showing a more decided 
advantage over the others. A greater understanding of the pathophysiology of PPH could guide the development of 
new therapeutic strategies.
Methods: We studied a cohort of PPH patients at the Imperial Weight Center. We performed continuous glucose 
monitoring to characterize their altered glycaemic variability. We also performed a mixed meal test (MMT) and 
measured gut hormone concentrations.
Results: We found increased glycaemic variability in our cohort of PPH patients, specifically a higher mean amplitude 
glucose excursion (MAGE) score of 4.9. We observed significantly greater and earlier increases in insulin, GLP-1 and 
glucagon in patients who had hypoglycaemia in response to an MMT (MMT Hypo) relative to those that did not 
(MMT Non-Hypo). No significant differences in oxyntomodulin, GIP or peptide YY secretion were seen between these 
two groups.
Conclusion: An early peak in GLP-1 and glucagon may together trigger an exaggerated insulinotropic response to 
eating and consequent hypoglycaemia in patients with PPH.
Introduction
The Roux-en-Y gastric bypass (RYGB) operation results in 
a rapid improvement in any pre-existing type 2 diabetes 
mellitus (T2DM) that occurs shortly after the operation 
prior to any significant weight loss (1, 2). Whilst the 
cause for this remains unclear, it is apparent that there 
is a dramatic alteration in glucose tolerance. Beyond a 
reduction in fasting and postprandial plasma glucose 
levels, there is also a change in the glucose tolerance 
curve. Instead of a steady increase in glucose that 
plateaus before returning to baseline, there is a sharp 
rise with a peak glucose at 30 min with a subsequent 
rapid drop (3).
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Glycaemic variability (GV) is broadly defined as the 
fluctuations between hyper and hypoglycaemia that 
typically occur in diabetes (4). There is also an increase 
in GV post-RYGB, relative to obese subjects who have 
not had RYGB surgery (5, 6, 7, 8, 9). Increased GV is 
not exclusive to RYGB patients with diabetes but is also 
observed in patients who are considered euglycaemic both 
before and after surgery (3, 10). It is now recognised that 
a proportion of patients after surgery develop disabling 
symptoms of postprandial hypoglycaemia (PPH) that are 
associated with this increased GV.
The reported prevalence of PPH varies from 0.1% 
(severe cases) to 13.3% (mild hypoglycaemia) but is 
likely under-reported due to a combination of vague 
symptoms, a lack of awareness of this condition and lack 
of agreement on diagnostic standards (10, 11). PPH after 
RYGB was first described by Service et  al. in 2005 in 6 
patients (12). However, cases of PPH occurring after partial 
gastrectomies for gastric ulcer disease have been reported 
since the 1930s (13). Understanding the pathophysiology 
is important as the increasing prevalence of patients who 
have undergone surgery means that PPH will become 
more and more common with time (14). Additionally, 
whilst it is established that severe hypoglycaemia can 
result in seizure or coma and even death, it is increasingly 
recognised that even mild hypoglycaemia can predispose 
to cardiac arrhythmias (15). Therefore, it is critical that 
PPH is recognised and treated.
The causes of PPH remain unclear. It has been long 
established that the hypoglycaemia is hyperinsulinaemic 
in nature but the underlying mechanism remains 
unknown. Previous work has focused on incretins 
(insulinotropic hormones that are secreted in response 
to an oral glucose load) and the exaggerated secretion of 
the incretin glucagon-like peptide-1 (GLP-1) (16). Some 
studies have shown elevated GLP-1 levels in patients 
with PPH relative to patients without PPH whilst others 
have failed to confirm this (16, 17, 18). Furthermore, 
both GLP-1 receptor antagonists and agonists have been 
shown to improve PPH, which is difficult to reconcile 
(19, 20).
To address these areas of uncertainty regarding the 
pathophysiology of PPH, we report our experience within 
the Imperial Weight Centre (IWC). We describe the 
dynamics of gut hormone secretion, notably peptide YY 
(PYY), GLP-1, glucagon and oxyntomodulin (OXM) and 
glycaemic variability in a cohort of patients referred to the 
IWC with PPH who underwent a mixed meal test (MMT) 
and CGM (continuous glucose monitoring).
Subjects and methods
Study design and participants
Patients with symptomatic PPH were identified from cases 
referred to the IWC. All patients were shown to experience 
episodes fulfilling Whipple’s triad for hypoglycaemia. 
Patients with fasting hypoglycaemia <3.0 mmol/L were 
excluded. Three of the RYGB patients had had surgery 
at another bariatric centre but were referred to the IWC 
for management of their symptomatic PPH. All subjects 
were assessed by an experienced physician to exclude 
alternative causes such as epilepsy or postural orthostatic 
tachycardia syndrome prior to further investigation.
One of the key issues with PPH is that patients do 
not consistently report symptoms with one type of 
meal or other provocation, and even when patients are 
consistently taking the same meal on different occasions, 
hypoglycaemia may not always occur. In the absence of a 
gold-standard diagnostic test, we took the approach that 
we would administer a standardised provocation test in 
the form of a liquid mixed meal test (MMT) with a fixed 
carbohydrate, fat and protein content. To determine if 
changes in gut hormone secretion in response to this 
trigger are associated with biochemical hypoglycaemia, 
these changes were compared between subjects that had 
biochemical hypoglycaemia during a MMT (MMT Hypo) 
and those that did not experience hypoglycaemia (MMT 
Non-Hypo).
Further control groups (obese subjects who have 
not undergone RYGB surgery and RYGB patients who 
were asymptomatic from PPH) were obtained from an 
on-going randomised controlled study currently being 
performed at Imperial College London (REC reference no: 
13/LO/1510).
Continuous glucose monitoring (CGM)
Subjects underwent a CGM study for 5 days, under free 
living conditions. Initially a Meditronic iPro2 system 
(Meditronic, Northridge, USA) was used, and in later 
studies, this was changed to Abbott FreeStyle Navigator II 
(Abbott). For both types of CGM, subjects were required 
to calibrate their machines with capillary blood glucose 
testing. For the Meditronic iPro2 system, four calibrations 
a day were performed whilst the Abbott FreeStyle 
Navigator II required calibration after 1, 2, 10, 24 and 72 h 
following sensor insertion. Data were analysed using the 
easyGV calculator for measures of GV (http://www.phc.
ox.ac.uk/research/technology-outputs/easygv; accessed: 
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6 January 2016). Measures of GV analysed included: 
standard deviation (s.d.), lability index (LI), mean of daily 
differences (MODD), mean amplitude glucose excursion 
(MAGE), glycaemic risk assessment in diabetes equation 
(GRADE), continuous overlapping net glycaemic action 
(CONGA), high blood glucose index (HBGI), low blood 
glucose index (LBGI), average daily risk ratio (ADRR) and 
mean absolute glucose (MAG).
Mixed meal test (MMT)
Subjects arrived at the investigation unit at 08:30 h 
having fasted overnight. A peripheral venous cannula 
was inserted for blood sampling. At 09:00 h, subjects 
consumed an Ensure Plus food supplement (13.8 g of 
protein, 10.8 g of fat, 44.4 g of carbohydrates, 330 kcal, 
220 mL, Abbott) within 10 min. Blood sampling for 
glucose, insulin, C-peptide and gut hormones were 
taken at thirty-minute intervals for four hours. In 
addition, a capillary blood glucose (CBG) sample 
was taken if subjects complained of hypoglycaemic 
symptoms. The study was stopped if subjects developed 
neurological symptoms of hypoglycaemia and had a 
CBG of ≤3.0 mmol/L. Biochemical hypoglycaemia was 
defined as a venous plasma glucose ≤3.0 mmol/L in 
keeping with the consensus guidelines on hypoglycaemia 
(21). The insulinogenic index was calculated as the 
ratio of incremental insulin concentration to glucose 
concentration at 30 min (22).
Glucose and insulin were measured by the Department 
of Chemical Pathology, Imperial College Healthcare 
NHS Trust using an Abbott Architect integrated system 
analyser with coefficients of variation (CV) of <5% and 
<7% respectively. Plasma samples for gut hormones were 
collected in lithium heparin tubes containing aprotinin 
(1000 kallikirein inhibitor units). Plasma total PYY and GIP 
were measured using the Milliplex magnetic bead-based 
multi-analyte, metabolic panel, 4-plex immunoassay 
(Millipore). The CV for each analyte was <10% and <15% 
with reference to intra- and inter-assay precision. The 
lowest level of quantification was 3.4 and 0.3 pmol/L for 
total PYY and GIP respectively. OXM was measured by 
a radioimmunoassay validated by mass spectroscopy as 
described in a previous study (23). The plasma total GLP-1 
and glucagon were measured using ELISAs from Mercodia 
(Uppsala, Sweden), with lowest levels of detection of 
1.0 and 1.5 pmol/L respectively. The cross-reactivity of 
the glucagon assay for OXM and GLP-1 was <4.4% and 
<0.3%. Quality controls co-delivered with the kits and 
run in parallel with the plasma samples were all within 
prespecified limits.
Statistical analysis
Statistical analysis was performed using Prism 6.0 
(GraphPad Software). Two-way repeated measures 
ANOVA with Bonferroni post hoc test was used to compare 
differences in glucose, insulin, total GLP-1, GIP, PYY and 
glucagon at different time points. One-way ANOVA with 
Tukey post hoc test was used to compare the differences 
in AUCs when more than two groups were being 
compared. Unpaired Student t-tests were used to compare 
differences between groups when only two groups were 
being compared. Normality of data was assessed by 
a D’Agostino–Pearson test. Comparisons of measures 
of glycaemic variability that did not have a Gaussian 
distribution was performed using a Wilcoxon test. Results 
are presented as mean ± s.e.m. and statistical significance 
defined as P < 0.05.
Results
The demographics of the recruited subjects are shown in 
Table 1. Eighteen subjects had symptomatic PPH (Table 2). 
Eight out of the 18 patients had T2DM prior to surgery, 
but all were in remission (as defined by the American 
Diabetes Association) after surgery (24). All patients had 
had RYGB at least 1 year prior to study. Two control groups 
were also analysed; a group of obese patients who had not 
had RYGB surgery (obese no-RYGB, N = 9) and a group 
consisting of RYGB patients who had not had symptoms 
of PPH (asymptomatic RYGB, N = 10).
Eleven subjects (patient numbers 8–18 from Table 2) 
with symptoms of PPH post-RYGB wore CGMs for five 
days. Their data was compared to a reference range for 
non-diabetic patients who have not had RYGB (4). The 
PPH patients had MAGE, ADDR and MAG values that 
were higher than the reference range (Table 3). Of these 11 
subjects, five developed hypoglycaemia during the MMT. 
When those patients that developed hypoglycaemia 
during the MMT were compared to those that did not 
develop hypoglycaemia during the MMT, there was no 
significant difference in measures of GV or proportion 
of time in hypoglycaemia between the two groups (data 
not shown). A further analysis was performed comparing 
glycaemic variability during the hours of 06:00–
22:00 (representing the awake period) to 22:00–06:00 
(representing the sleep period). Glycaemic variability was 
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increased in the day time relative to night time for all 
measures except for GRADE (Table 3).
Eighteen symptomatic PPH subjects and 19 subjects 
from the two control groups underwent a MMT 
(Fig.  1, Supplementary Tables  1 and 2, see section on 
supplementary data given at the end of this article). 
There was no significant difference in the fasting glucose 
concentration between the three groups. Thirty minutes 
following the consumption of the mixed meal, there was 
a significant difference in plasma glucose concentration 
between both surgical cohorts relative to Obese-No 
RYGB group (glucose30: 9.0 ± 0.4 (symptomatic PPH 
group), 9.4 ± 0.8 (asymptomatic RYGB), 6.0 ± 0.4 mmol/L 
(Obese-No RYGB) – P < 0.0001 both for comparison of 
symptomatic PPH vs Obese-No RYGB and for comparison 
of asymptomatic RYGB vs Obese-No RYGB). Plasma glucose 
levels fell to baseline by 120 min and there appeared to 
be no significant difference in mean glucose levels at this 
timepoint between the PPH and asymptomatic RYGB 
groups (Glucose120: 4.8 ± 0.2 (asymptomatic RYGB) vs 
4.0 ± 0.3 mmol/L (symptomatic PPH group), P = NS for 
comparison).
There was no significant difference in the fasting 
concentration of insulin between all three groups. 
Thirty minutes following the consumption of the 
mixed meal, there was a significant difference in serum 
insulin concentration between both surgical cohorts 
relative to Obese-No RYGB group (Insulin30: 132.0 ± 24.8 
(symptomatic PPH group), 119.4 ± 24.9 (asymptomatic 
RYGB), 39.9 ± 7.4 U/L (Obese-No RYGB – P < 0.0001 both 
for comparison of symptomatic PPH vs Obese-No RYGB 
and for comparison of asymptomatic RYGB vs Obese-No 
RYGB). In both RYGB groups, the serum insulin returned 
to baseline at 120 min whilst the Obese-No RYGB group’s 
serum insulin was more persistently elevated at 120 min 
(insulin120:7.8 ± 1.1 (asymptomatic RYGB) vs 13.0 ± 4.2 
(symptomatic PPH group) vs 38.1 ± 8.9 U/L (Obese-No 
RYGB) – P = NS for comparisons between groups).
Table 1 Demographics of all subjects in study. Data is shown as mean ± s.e.m.
 Symptomatic PPH Obese-No RYGB controls Asymptomatic RYGB controls
Number of subjects 18 9 10
Gender 10F, 8M 7F, 2M 9F, 1M
Age (years) 47.5 ± 2.4 43.6 ± 3.9 46.7 ± 4.2
HbA1c (mmol/mol) 38.4 ± 1.2 39.8 ± 1.7 39.2 ± 1.4
Presurgical weight (kg) 130.1 ± 4.6  131.4 ± 3.5
Percentage weight loss at 1 year (%) 32.2 ± 1.6  31.1 ± 2.3
F, female; M, male.
Table 2 Demographics of subjects with PPH.
Patient 
No.
Year of 
surgery
 
Type of surgery
 
Age (years)
Diabetes pre 
surgery
Presurgical 
weight (kg)
Percentage weight 
loss at 1 year (%)
Onset of symptoms 
from surgery (years)
1 2010 RYGB 50 Yes 117 32 2
2 2010 RYGB 60 No 118 28 1
3 2011 RYGB 52 Yes 127 35 2
4 2012 RYGB 46 Yes 118 29 1
5 2011 RYGB 43 Yes 153 43 2
6 2013 RYGB 33 No 138 33 1
7 2007 RYGB 51 No 138 33 6
8 2010 RYGB 52 No 130 37 1
9 2007 RYGB 44 Yes 126 41 3
10 2007 RYGB 26 No 151 27 3
11 2010 RYGB 44 Yes 131 33 2
12 2010 RYGB 51 Yes 98 38 1
13 2012 RYGB 46 No 167 31 1
14 2010 RYGB 71 Yes 121 36 3
15 2013 RYGB 33 No 168 25 1
16 2012 RYGB* 55 No 121 12 2
17 2014 RYGB 48 No 104 33 1
18 2012 RYGB 50 No 115 34 3
*conversion from sleeve RYGB, Roux-en-Y Gastric Bypass.
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Seven of the 18 PPH patients had plasma glucose 
concentrations below 3.0 mmol/L between 60 and 120 min 
following an MMT. To further investigate the gut hormone 
dynamics that trigger PPH, the data were categorised 
into those that had biochemical hypoglycaemia of 
<3.0 mmol/L during the course of the MMT (MMT 
Hypo) and those that did not (MMT Non-Hypo). Whilst 
the seven MMT Hypo patients were symptomatic, none 
of them developed severe neurological symptoms that 
required treatment.
Glucose and insulin responses to the MMT are shown 
in Fig. 2 and Supplementary data. The peak glucose was 
not different between the MMT Hypo and Non-Hypo 
group (9.5 ± 0.7 (MMT Hypo group) vs 9.2 ± 0.4 mmol/L 
(MMT Non-Hypo group)). As expected, the MMT Hypo 
group had a significantly lower nadir glucose relative 
to the MMT Non-Hypo group (nadir glucose 2.4 ± 0.2 
(MMT Hypo group) vs 3.9 ± 0.1 mmol/L (MMT Non-Hypo 
group)). With reference to the glycaemic profile, there was 
no other significant difference between the two groups.
There was no significant difference in the baseline 
insulin concentration between the two groups. However, 
after consuming the mixed meal, the MMT Hypo group 
had a significantly higher mean peak serum insulin 
concentration at 30 min (insulin30 232.7 ± 25.0 (MMT 
Hypo group) vs 102.2 ± 22.7 U/L (MMT Non-Hypo group) 
P < 0.05). There was no significant difference in the AUC 
insulin but the MMT Hypo group had a higher insulin 
response relative to their plasma glucose as evidenced by 
a significant difference in the insulinogenic index and the 
ratio of AUC insulin: glucose (Supplementary Table 2).
Baseline fasting glucagon levels were not significantly 
different between the MMT Hypo group and the MMT 
Non-Hypo group (5.3 ± 1.3 (MMT Hypo group) vs 
5.6 ± 0.7 pmol/L (MMT Non-Hypo group) – Fig.  2E). 
Following ingestion of the mixed meal, the glucagon 
concentration increased in both the MMT Hypo group 
at 30 min (glucagon30 31.1 ± 6.0 (MMT Hypo group) 
vs 21.7 ± 3.4 pmol/L (MMT Non-Hypo group), P = 0.07) 
and at 60 min (glucagon60 21.3 ± 4.3 (MMT Hypo group) 
vs 12.4 ± 1.7 pmol/L (MMT Non-Hypo group), P = NS). 
Although there was a trend towards elevated glucagon 
levels at 30 min in the MMT Hypo group compared 
to the MMT Non-Hypo group, this difference was not 
statistically significant. However, the mean AUC glucagon 
for the MMT Hypo group was significantly higher 
(3677 ± 689.5 pmol/L.min) compared to the MMT Non-
Hypo group (2279 ± 230.3 pmol/L.min, unpaired t-test, 
P = 0.0368).
Baseline fasting total GLP-1 levels were also not 
significantly different between the MMT Hypo and 
the MMT Non-Hypo groups (8.7 ± 2.5 (MMT Hypo 
group) vs 14.9 ± 3.7 (MMT Non-Hypo group) – Fig. 2C). 
Following ingestion of the mixed meal, the GLP-1 
concentration increased in both the MMT Hypo and 
MMT Non-Hypo groups at 30 min (GLP-130 246.0 ± 15.3 
Table 3 Measurement of parameters of glycaemic variability in PPH patients.
  Symptomatic PPH (N = 11)
GV measure  Reference range Awake (06:00–22:00) Asleep (22:00–06:00) Total
s.d. 0.0–3.0 1.8 ± 0.7** 1.2 ± 0.1 1.8 ± 0.2
CONGA 3.6–5.5 4.8 ± 0.1*** 4.2 ± 0.1 4.6 ± 0.2
LI 0.0–4.7 5.1 ± 0.6** 3.1 ± 0.7 4.7 ± 0.8
J-INDEX 4.7–23.6 18.8 ± 1.2*** 13.8 ± 1.1 18.4 ± 1.9
LBGI 0.0–6.9 3.8 ± 0.7** 5.4 ± 0.8 4.9 ± 1.1
HBGI 0.0–7.7 3.5 ± 0.5** 1.8 ± 0.4 3.4 ± 0.7
GRADE 0.0–4.6 2.2 ± 0.9 1.8 ± 0.4 1.2 ± 0.2
MODD 0.0–3.5 N/A N/A 1.5 ± 0.1
MAGE 0.0–2.8 5.0 ± 0.4*** 2.6 ± 0.3 4.9 ± 0.4
ADDR 0.0–8.7 N/A N/A 12.0 ± 2.9
M Value 0.0–12.5 6.7 ± 1.5* 10.1 ± 2.6 9.4 ± 2.7
MAG 0.5–2.2 2.3 ± 0.1* 1.8 ± 0.1 2.3 ± 0.2
% time in hypoglycemia <3.0  2.4 ± 1.4 1.7 ± 1.1 2.0 ± 0.9
% time in range, 3.0–7.0  76.0 ± 4.0 86.8 ± 2.7 81.4 ± 2.6
% time in hyperglycemia >7.0  21.6 ± 3.7 11.6 ± 2.8 16.6 ± 2.5
*P value <0.01, **P value <0.001 and ***P value <0.0001.
ADRR, average daily risk ratio; CONGA, continuous overlapping net glycaemic action; GRADE, glycaemic risk assessment in diabetes equation; HBGI, high 
blood glucose index; LBGI, low blood glucose index; LI, lability index; MAG, mean absolute glucose; MAGE, Mean Amplitude Glucose Excursion; MODD, 
mean of daily differences; s.d., standard deviation.
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(MMT  Hypo  group) vs 137.3 ± 23.4 pmol/L (MMT Non-
Hypo group), P < 0.0001), but significantly more in the 
MMT Hypo group.
There was no significant difference in concentrations 
of total PYY, GIP and OXM at any time point during 
the MMT between both groups, nor in the AUC (Fig. 2B, 
D and G).
Discussion
This study has demonstrated the altered physiology 
of glucose handling that occurs after RYGB surgery 
through two different clinical tests, continuous 
glucose monitoring and mixed meal testing. For our 
particular study, we have chosen a pragmatic definition 
of PPH which is based on the clear demonstration 
of biochemical hypoglycaemia in association with 
Whipple’s triad. Previous studies have compared 
bariatric surgery patients known to have symptomatic 
PPH with a group of asymptomatic patients. Salehi et al. 
have previously demonstrated a significantly lower 
glucose nadir in those that have a history of PPH (25), 
but this was not replicated in a subsequent study by 
the same authors (18) or by others such as Goldfine 
et  al. (16) and Laurenius et  al. (17). This disparity 
A
B
Figure 1
Changes in plasma glucose (A) and serum insulin (B) following 
a MMT in patients with symptomatic PPH, a non-surgical 
obese group and an asymptomatic RYGB group. Mixed meal 
was given at T = 0. Numbers of subjects in each group shown 
in brackets. Data is shown as mean ± s.e.m. Statistically 
significant differences are shown as *PPH vs Obese-No RYGB 
P < 0.001, asymptomatic-RYGB vs Obese-No RYGB P < 0.001. 
**PPH vs Obese-No RYGB P < 0.001.
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Figure 2
Changes in glucose (A) and insulin (B) serum GLP-1 (C), GIP (D), 
glucagon (E), peptide YY (F), and OXM (G) following a MMT 
in patients with symptomatic PPH. Patients classified as either 
MMT Hypo (n = 7) or MMT Non-Hypo (n = 11), depending if 
their nadir glucose was <3 mmol/L. Data is shown as 
mean ± s.e.m. Statistically significant differences are shown as 
**P < 0.01, ***P < 0.0001.
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between studies is explained by the failure of the 
provocation test used to induce hypoglycaemia in all 
the PPH patients whilst some within the asymptomatic 
group developed biochemical hypoglycaemia without 
symptoms (18,  25). This illustrates two important 
observations. First, in the RYGB cohort, there is a high 
prevalence of asymptomatic hypoglycaemia. This may 
be due to hypoglycaemic unawareness and attenuated 
counter-regulatory responses in patients post RYGB (26). 
Secondly, in patients with PPH, the reproduction of this 
condition with dynamic testing appears variable. In our 
cohort, only 7 of 18 were shown to have biochemical 
hypoglycaemia after a mixed meal provocation. For 
non-bariatric patients who are suspected to have PPH, 
the MMT is recommended as the gold standard test (21). 
On the other hand, there is no gold standard test to 
diagnose PPH in bariatric surgery patients and within the 
literature many tests have been used such as prolonged 
oral glucose tolerance test, MMT and CGM (17, 25).
Altered glycaemic variability post RYGB
Subjects with symptomatic PPH were shown to have 
increased GV as measured by CGM, although there was 
no difference in measures of GV between the subgroup 
that experienced a hypo in response to the MMT vs those 
that did not. Specifically, MAGE, ADDR and MAG were 
increased relative to normal limits defined by Hill et al. 
in 70 non-RYGB operated euglycaemic subjects (21). 
Similar findings were made in a separate study by Hanaire 
et al. who demonstrated an increase in MAGE in 10 PPH 
patients of 4.8 ± 3.3 (8).
MAGE and MAG assess glucose excursions from 
the mean glucose level with the former designed 
specifically for postprandial changes. ADDR assesses 
the prevalence of glucose values outside the normal 
range and hence is a good predictor for both hyper- and 
hypoglycaemia  (27). The changes in these parameters 
of GV highlight the altered glucose tolerance observed 
after RYGB surgery, which is seen in the data from the 
MMT. GV, in our cohort of patients, was significantly 
higher as assessed by multiple parameters during 06:00–
22:00 (awake period) compared to 22:00–06:00 (asleep), 
possibly due to differences in the diurnal rhythms of 
metabolism and hormone secretion, physical activity 
and food intake. A limitation of the present analysis 
is that no specific data were collected to enable an 
analysis of the relationship of exercise and food intake 
to glycaemia, and future studies should examine any 
impacts of these factors on the development of PPH.
Altered glucose tolerance in patients post RYGB 
measured by a MMT
This study has demonstrated that patients post-RYGB 
have an altered glucose tolerance relative to a control 
group of obese euglycaemic individuals, independently of 
whether they have PPH. The altered glucose tolerance is 
characterised by significantly earlier and higher glucose 
peak concentration following consumption of a mixed 
meal. These data are consistent with previous reports (3).
The higher peak concentration of glucose in the RYGB 
patients is in keeping with accelerated nutrient entry and 
absorption after bypass (28). Although all the studied 
RYGB patients had normal glycated haemoglobin, they 
had an increase in GV which has been shown to be an 
independent risk factor for an increase in microvascular 
complications (29). Miras et al. in a prospective case series 
demonstrated an improvement in nephropathy at one 
year post surgery, but this was not shown for retinopathy 
or neuropathy (7). Furthermore, a recent meta-
analysis investigating the effects of bariatric surgery on 
retinopathy revealed that whilst 19.2 ± 12.9% of patients 
had improvements, 23.5±18.7% had a deterioration in 
retinopathy (9). More reassuringly, the SOS study, a non-
randomised case-controlled study comparing bariatric 
surgery to lifestyle management, demonstrated significant 
reductions in the cumulative incidence of macrovascular 
and microvascular events in the bariatric surgery group 
compared to a control group when followed up for up 
to 20  years (5). Nevertheless, this example shows that 
even if bariatric surgery is capable of improving HbA1c 
in diabetics to ‘normal’, patients remain at risk of 
developing microvascular complications post-operatively, 
and increased GV may well be a key driver for this process.
Differences in glucose, insulin and gut hormones, 
between RYGB patients who have biochemical 
hypoglycaemia and those that do not, during a MMT
The CGM data demonstrated that patients with PPH spent 
3.7% of their time in a hypoglycaemic range. Whilst these 
episodes occurred in the postprandial phase, they did not 
occur after every meal suggesting that the occurrence of 
hypoglycaemia is a variable phenomenon. One factor 
that has been postulated to precipitate hypoglycaemia 
is a high glycaemic index (GI) meal resulting in an 
increased glucose excursion followed by an exaggerated 
insulin response precipitating hypoglycaemia; the ‘over-
swing phenomenon’. Indeed, Kellogg et al. has shown an 
improvement in PPH with a low GI diet (30). However, 
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in this study, no significant difference in the peak 
glucose concentrations was demonstrated between RYGB 
patients that had hypoglycaemia and those that did not. 
The patients that subsequently had hypoglycaemia did 
have a significantly higher insulin peak suggesting an 
increased insulin response to glucose concentrations, 
i.e. an increased insulinogenic index.
What could be driving this increased insulin 
secretion? An increased GLP-1 post-prandial response 
has been implicated (16). In this study, we also observed 
an acute elevation in peak total GLP-1 concentrations 
within 30 min, significantly higher in those that had 
hypoglycaemia in response to MMT vs those that did not 
have hypoglycaemia. Consistent with this observation, 
a subcutaneous bolus of GLP-1 can induce a reactive 
hypoglycaemia in response to a bolus of IV glucose 
in people with normal glucose tolerance, i.e. an acute 
elevation in GLP-1 levels is able to induce an excessive 
insulinotropic response to carbohydrates and consequent 
hypoglycaemia (31). Furthermore, antagonism of the 
GLP-1 receptor with exendin 9–39 has been shown to 
rescue PPH in RYGB patients (19, 32).
On the other hand, Abrahamsson et al. have described 
cases of successful treatment of PPH with liraglutide (20), 
and we have observed that this is indeed effective in 
ameliorating PPH in one of our patients (Supplementary 
Fig. 1). It is counterintuitive that a GLP-1 analogue could 
improve PPH (33). We believe that liraglutide is effective as 
it is present at fairly constant levels over extended periods 
of time, acting to slow down small bowel transit, leading 
to the reduced glycaemic impact of a meal entering the 
jejunum via the bypass and minimizing the potential 
to cause hypoglycaemia (34). GLP-1’s known action of 
slowing gastric emptying is unlikely to contribute to its 
beneficial effect in PPH (34, 35, 36) as RYGB patients have 
a small gastric pouch, which rapidly empties, and as any 
acute effect on gastric motility is subject to tachyphylaxis 
(36, 37). Therefore, it seems that the kinetics of GLP-1 are 
crucial in influencing the insulinotropic response in PPH, 
where acute spikes can induce hypoglycaemia, but more 
constant levels are associated with an amelioration.
Turning our attention to the other proglucagon 
derivatives, we found that there was no difference in OXM 
secretion in response to the MMT between the MMT Hypo 
and MMT Non-Hypo groups. There was an early increase 
in glucagon secretion in response to the MMT in the PPH 
patients studied, and the AUC glucagon in the MMT Hypo 
was greater than that in the MMT Non-Hypo group. This 
peak of glucagon occurs prior to any hypoglycaemia, 
suggesting a role in the pathology of PPH as opposed to a 
counter-regulatory action in response to hypoglycaemia. 
As GLP-1 and glucagon in combination are highly 
insulinotropic, the coincident, early elevations in both 
GLP-1 and glucagon are the likely triggers of the excess 
insulin secretion observed in the MMT Hypo group (38).
The mechanism for elevated postprandial glucagon 
following RYGB surgery is not entirely known. 
Whilst  the  source of glucagon was previously ascribed 
to the pancreas, it is difficult to see how the early 
secretion of glucagon (prior to hypoglycaemia) we have 
observed, in parallel with GLP-1, might originate from 
the pancreas. More recent data have demonstrated that 
there is extra-pancreatic glucagon secretion in patients 
post pancreatectomy, who have a quite similar Roux-
en-Y type bypass of the stomach to the jejeunum (39, 40). 
Speculatively, there may be an aberrant processing of 
proglucagon in L cells, leading to the early co-secretion 
of GLP-1 and glucagon in response to the meal stimulus 
prior to any hypoglycaemia.
In conclusion, these studies have demonstrated 
some significant findings relating to the rapid glucose 
fluctuations that occur in PPH and the underlying 
hormonal changes that drive it. There is an increased 
glycaemic variability observed in PPH with patients 
being hypoglycaemic for a significant proportion of the 
day. This study has highlighted an association between 
elevated GLP-1, glucagon and the hyperinsulinaemic 
hypoglycaemia observed in this condition. In future 
work, it will be necessary to test the effect of combined 
GLP-1 and glucagon antagonism in PPH patients to 
understand the relative contributions of these hormones 
in the pathophysiology of PPH.
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